Compare SSL & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSL | HAE |
|---|---|---|
| Founded | 1950 | 1971 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.7B |
| IPO Year | N/A | 1991 |
| Metric | SSL | HAE |
|---|---|---|
| Price | $6.50 | $80.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $88.38 |
| AVG Volume (30 Days) | ★ 769.7K | 712.4K |
| Earning Date | 02-23-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.54 |
| EPS | 0.59 | ★ 3.44 |
| Revenue | ★ $14,028,282,389.00 | $1,327,850,000.00 |
| Revenue This Year | $0.47 | N/A |
| Revenue Next Year | $5.51 | $6.01 |
| P/E Ratio | ★ $10.82 | $23.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.78 | $47.32 |
| 52 Week High | $7.39 | $87.32 |
| Indicator | SSL | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 56.20 |
| Support Level | $6.36 | $79.41 |
| Resistance Level | $6.47 | $80.94 |
| Average True Range (ATR) | 0.13 | 1.74 |
| MACD | 0.04 | -0.93 |
| Stochastic Oscillator | 81.73 | 19.45 |
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: the Southern Africa Energy & Chemicals business and the International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business, which operates integrated value chains with feedstock sourced from the Mining and Gas operating segments. Geographically, the company generates the majority of its revenue from South Africa.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.